drugset / Trial / NCT03901781
Study of ST266 Given by Intranasal Delivery in Glaucoma Suspect Subjects
Non-randomizedSequentialOpen-labelTreatment
Summary
The primary objective of this trial is to assess the safety of ST266 given by non-invasive intranasal trans-cribriform delivery to glaucoma suspect subjects with ocular hypertension, optic nerve cupping, or family history of glaucoma.
Timeline
- Start
- 2019-10-23
- Primary completion
- 2022-05-20
- Completion
- 2022-05-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ST266 | Protein / enzyme biologic | 0.2 ml | Intranasal |
| Subject | ST266 | Protein / enzyme biologic | 0.4 ml | Intranasal |